Stocks · News reference
Why Is GH Research Stock Trading Higher on Thursday?
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 16, 2026, 4:36 PM
- Checked
- Jul 16, 2026, 4:36 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
Read original at benzingaCoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.
Read original at benzingaDeutsche Bank Downgrades AtaiBeckley to Hold, Lowers Price Target to $8
Deutsche Bank analyst David Hoang downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Hold and lowers the price target from $12 to $8.
Read original at benzingaHC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $65
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target from $70 to $65.
Read original at benzingaMorgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $18
Morgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $17 to $18.
Read original at benzinga